SCHEMBL18280797

SCHEMBL18280797

CCCCCCCCOC(=O)[C@H](O)CCC(=O)O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 1/20 0.52
FFAR4 Q5NUL3 2/20 0.51
FFAR1 O14842 2/20 0.51
PLA2G2C Q5R387 1/20 0.49
GPR84 Q9NQS5 7/20 0.48
PPARG P37231 7/20 0.48
PPARD Q03181 7/20 0.48
PPARA Q07869 7/20 0.48
HDAC11 Q96DB2 5/20 0.48
TSHR P16473 4/20 0.48
PTPN1 P18031 3/20 0.48
ALDH1A1 P00352 2/20 0.48
TLR2 O60603 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
FABP4 P15090 2/20 0.48
SLC22A6 Q4U2R8 1/20 0.48
SLC22A8 Q8TCC7 1/20 0.48
MEN1 O00255 1/20 0.48
ESR1 P03372 1/20 0.48
ALOX15 P16050 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17010716 1.00 NAAA (0.52) NAAAFFAR4FFAR1PLA2G2CGPR84
SCHEMBL17010718 1.00 NAAA (0.52) NAAAFFAR4FFAR1PLA2G2CGPR84
SCHEMBL16553093 0.93 TET2 (0.47) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL28591540 0.86 NAAA (0.61) NAAAMEN1KMT2A
SCHEMBL31648087 0.86 NAAA (0.61) NAAAMEN1KMT2A
SCHEMBL28591704 0.86 NAAA (0.61) NAAAMEN1KMT2A
SCHEMBL9220597 0.85 NAAA (0.59) NAAAFFAR1GPR84TSHR
SCHEMBL13002969 0.85 GPR84 (0.59) NAAAFFAR1GPR84TSHR
SCHEMBL8375622 0.85 GPR84 (0.59) NAAAFFAR1GPR84TSHR
SCHEMBL6864319 0.85 GPR84 (0.59) NAAAFFAR1GPR84TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190133980-A1 Compositions and methods for targeting and treating homologous recombination-deficient tumors UNIV YALE (US) 2019-05-09 US claimed
US-20160354334-A1 Compositions and Methods for Treating Aging and Age-Related Diseases and Symptoms NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-12-08 US claimed
EP-3104852-B1 COMPOSITIONS AND METHODS FOR TREATING AGING AND AGE-RELATED DISEASES AND SYMPTOMS UNIV CALIFORNIA (US) 2024-08-14 EP disclosed
US-20230218559-A1 Compositions and Methods for Treating Aging and Age-Related Diseases and Symptoms UNIV CALIFORNIA (US) 2023-07-13 US disclosed
EP-3535025-B1 COMPOSITION COMPRISING R-2-HYDROXYGLUTARATE AND ONE AGENT THAT INHIBITS MYC SIGNALING FOR TREATING CANCER UNIV CINCINNATI (US) 2023-06-28 EP disclosed
US-20230144845-A1 Alpha-Ketobutyrate, 2-Hydroxybutyrate, and Alpha-Ketoglutarate for Stimulating Hair Growth UNIV CALIFORNIA (US) 2023-05-11 US disclosed
US-11179360-B2 Compositions and methods for treating patients suffering from glioma or leukemia UNIVERSITY OF CINCINNATI (US) 2021-11-23 US disclosed
US-11007163-B2 Glutarate compounds for treating ischemia-reperfusion injuries THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-05-18 US disclosed
US-20200253907-A1 Compositions and Methods for Treating Neurodegenerative Diseases UNIV CALIFORNIA (US) 2020-08-13 US disclosed
EP-3672583-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES The Regents of the University of California (US) 2020-07-01 EP disclosed
US-20200069621-A1 Glutarate Compounds for Treating Ischemia-Reperfusion Injuries UNIV CALIFORNIA (US) 2020-03-05 US disclosed
US-10285962-B2 Glutarate compounds for treating ischemia-reperfusion injuries THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-05-14 US disclosed
US-20190133980-A1 Compositions and methods for targeting and treating homologous recombination-deficient tumors UNIV YALE (US) 2019-05-09 US disclosed
EP-3453046-A1 GLUTARATE COMPOUNDS FOR TREATING ISCHEMIA-REPERFUSION INJURIES The Regents of the University of California (US) 2019-03-13 EP disclosed
WO-2019038655-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-02-28 WO disclosed
WO-2018064468-A1 ALPHA-KETOBUTYRATE, ALPHA-KETOGLUTARATE, AND 2-HYDROXYBUTYRATE FOR STIMULATING HAIR GROWTH THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-04-05 WO disclosed
WO-2017210608-A1 COMPOSITIONS AND METHODS FOR TARGETING AND TREATING HOMOLOGOUS RECOMBINATION-DEFICIENT TUMORS YALE UNIVERSITY (US) 2017-12-07 WO disclosed
US-20170333373-A1 Glutarate Compounds for Treating Ischemia-Reperfusion Injuries THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2017-11-23 US disclosed
WO-2017192413-A1 GLUTARATE COMPOUNDS FOR TREATING ISCHEMIA-REPERFUSION INJURIES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-11-09 WO disclosed
US-20160354334-A1 Compositions and Methods for Treating Aging and Age-Related Diseases and Symptoms NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200069621-A1 Glutarate Compounds for Treating Ischemia-Reperfusion Injuries GCDH, OGDH, GLS NAAA 2735/4885FFAR4 1359/4885FFAR1 673/4885
US-20160354334-A1 Compositions and Methods for Treating Aging and Age-Related Diseases and Symptoms GLA, GCDH, HAGH NAAA 595/4885FFAR4 3002/4885FFAR1 2528/4885
US-11007163-B2 Glutarate compounds for treating ischemia-reperfusion injuries GCDH, OGDH, GLS NAAA 2735/4885FFAR4 1359/4885FFAR1 673/4885
US-20200253907-A1 Compositions and Methods for Treating Neurodegenerative Diseases SNCA, PSEN2, PSEN1 NAAA 221/4885FFAR4 3725/4885FFAR1 2888/4885
US-20170333373-A1 Glutarate Compounds for Treating Ischemia-Reperfusion Injuries GCDH, OGDH, GLS NAAA 2735/4885FFAR4 1359/4885FFAR1 673/4885
US-20230218559-A1 Compositions and Methods for Treating Aging and Age-Related Diseases and Symptoms GCDH, GLA, GRHPR NAAA 805/4885FFAR4 2783/4885FFAR1 2219/4885
US-20230144845-A1 Alpha-Ketobutyrate, 2-Hydroxybutyrate, and Alpha-Ketoglutarate for Stimulating Hair Growth HOGA1, GCDH, LDHB NAAA 2263/4885FFAR4 1617/4885FFAR1 1075/4885
US-11179360-B2 Compositions and methods for treating patients suffering from glioma or leukemia MYC, IDH1, OGDH NAAA 2650/4885FFAR4 4042/4885FFAR1 3543/4885
US-10285962-B2 Glutarate compounds for treating ischemia-reperfusion injuries GCDH, OGDH, GLS NAAA 2735/4885FFAR4 1359/4885FFAR1 673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.